16 citations · 36 across the 6 of their papers we have counts for
4 papers · 1 filter
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
Kaspar Rufibach, Lynda Grinsted, Jiang Li +3
For the analysis of a time-to-event endpoint in a single-arm or randomized clinical trial it is generally perceived that interpretation of a given estimate of the survival function…
The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies
Jonathan M Siegel, Hans-Jochen Weber, Stefan Englert
The ICH E9 (R1) Estimands Guidance1 terminology does not completely address the conceptual needs of time-to-event estimands in the complex oncology context. We previously described…
Time-to-event estimands and loss to follow-up in oncology in light of the estimands framework
Jonathan Siegel, Hans-Jochen Weber, Stefan Englert +1
Time-to-event estimands are central to many oncology clinical trials. The estimand framework (addendum to the ICH E9 guideline) calls for precisely defining the treatment effect of…